Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 118

1.

Contribution of the activities of CYP3A, CYP2D6, CYP1A2 and other potential covariates to the disposition of methadone in patients undergoing methadone maintenance treatment.

Shiran MR, Lennard MS, Iqbal MZ, Lagundoye O, Seivewright N, Tucker GT, Rostami-Hodjegan A.

Br J Clin Pharmacol. 2009 Jan;67(1):29-37. doi: 10.1111/j.1365-2125.2008.03312.x.

2.

Effect of fluvoxamine therapy on the activities of CYP1A2, CYP2D6, and CYP3A as determined by phenotyping.

Kashuba AD, Nafziger AN, Kearns GL, Leeder JS, Gotschall R, Rocci ML Jr, Kulawy RW, Beck DJ, Bertino JS Jr.

Clin Pharmacol Ther. 1998 Sep;64(3):257-68.

PMID:
9757149
3.

Pharmacokinetics and pharmacodynamics of methadone enantiomers after a single oral dose of racemate.

Boulton DW, Arnaud P, DeVane CL.

Clin Pharmacol Ther. 2001 Jul;70(1):48-57.

PMID:
11452244
4.

A discordance between cytochrome P450 2D6 genotype and phenotype in patients undergoing methadone maintenance treatment.

Shiran MR, Chowdry J, Rostami-Hodjegan A, Ellis SW, Lennard MS, Iqbal MZ, Lagundoye O, Seivewright N, Tucker GT.

Br J Clin Pharmacol. 2003 Aug;56(2):220-4.

5.

Pharmacokinetic-pharmacodynamic modeling of mood and withdrawal symptoms in relation to plasma concentrations of methadone in patients undergoing methadone maintenance treatment.

Shiran MR, Lennard MS, Iqbal MZ, Lagundoye O, Seivewright N, Tucker GT, Rostami-Hodjegan A.

J Clin Psychopharmacol. 2012 Oct;32(5):666-71. doi: 10.1097/JCP.0b013e3182664ecd.

PMID:
22926601
6.

Temporal changes in drug metabolism (CYP1A2, CYP2D6 and CYP3A Activity) during pregnancy.

Tracy TS, Venkataramanan R, Glover DD, Caritis SN; National Institute for Child Health and Human Development Network of Maternal-Fetal-Medicine Units.

Am J Obstet Gynecol. 2005 Feb;192(2):633-9.

PMID:
15696014
7.

ABCB1 and cytochrome P450 genotypes and phenotypes: influence on methadone plasma levels and response to treatment.

Crettol S, Déglon JJ, Besson J, Croquette-Krokar M, Hämmig R, Gothuey I, Monnat M, Eap CB.

Clin Pharmacol Ther. 2006 Dec;80(6):668-81.

PMID:
17178267
8.

Cytochrome P4503A4 metabolic activity, methadone blood concentrations, and methadone doses.

Shinderman M, Maxwell S, Brawand-Amey M, Golay KP, Baumann P, Eap CB.

Drug Alcohol Depend. 2003 Mar 1;69(2):205-11.

PMID:
12609702
9.

Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone.

Kharasch ED, Hoffer C, Whittington D, Sheffels P.

Clin Pharmacol Ther. 2004 Sep;76(3):250-69.

PMID:
15371986
10.

Comparative in vitro and in vivo inhibition of cytochrome P450 CYP1A2, CYP2D6, and CYP3A by H2-receptor antagonists.

Martínez C, Albet C, Agúndez JA, Herrero E, Carrillo JA, Márquez M, Benítez J, Ortiz JA.

Clin Pharmacol Ther. 1999 Apr;65(4):369-76.

PMID:
10223772
11.

Impact of fraction unbound, CYP3A, and CYP2D6 in vivo activities, and other potential covariates to the clearance of tramadol enantiomers in patients with neuropathic pain.

de Moraes NV, Lauretti GR, Coelho EB, Godoy AL, Neves DV, Lanchote VL.

Fundam Clin Pharmacol. 2016 Apr;30(2):153-61. doi: 10.1111/fcp.12168. Epub 2015 Dec 11.

PMID:
26947771
12.

Determinants of interindividual variability and extent of CYP2D6 and CYP1A2 inhibition by paroxetine and fluvoxamine in vivo.

Ozdemir V, Naranjo CA, Shulman RW, Herrmann N, Sellers EM, Reed K, Kalow W.

J Clin Psychopharmacol. 1998 Jun;18(3):198-207.

PMID:
9617978
13.

Lack of influence of CYP2D6 genotype on the clearance of (R)-, (S)- and racemic-methadone.

Coller JK, Joergensen C, Foster DJ, James H, Gillis D, Christrup L, Somogyi AA.

Int J Clin Pharmacol Ther. 2007 Jul;45(7):410-7.

PMID:
17725248
14.

In vivo effects of interleukin-10 on human cytochrome P450 activity.

Gorski JC, Hall SD, Becker P, Affrime MB, Cutler DL, Haehner-Daniels B.

Clin Pharmacol Ther. 2000 Jan;67(1):32-43.

PMID:
10668851
15.

Effect of an antiretroviral regimen containing ritonavir boosted lopinavir on intestinal and hepatic CYP3A, CYP2D6 and P-glycoprotein in HIV-infected patients.

Wyen C, Fuhr U, Frank D, Aarnoutse RE, Klaassen T, Lazar A, Seeringer A, Doroshyenko O, Kirchheiner JC, Abdulrazik F, Schmeisser N, Lehmann C, Hein W, Schömig E, Burger DM, Fätkenheuer G, Jetter A.

Clin Pharmacol Ther. 2008 Jul;84(1):75-82. doi: 10.1038/sj.clpt.6100452. Epub 2008 Jan 9.

16.

Therapeutic drug monitoring in methadone maintenance: choosing a matrix.

Moolchan ET, Umbricht A, Epstein D.

J Addict Dis. 2001;20(2):55-73. Review.

PMID:
11318398
17.

Steady-state pharmacokinetics of (R)- and (S)-methadone in methadone maintenance patients.

Foster DJ, Somogyi AA, Dyer KR, White JM, Bochner F.

Br J Clin Pharmacol. 2000 Nov;50(5):427-40.

18.

Cytochrome P450 2D6 genotype and methadone steady-state concentrations.

Eap CB, Broly F, Mino A, Hämmig R, Déglon JJ, Uehlinger C, Meili D, Chevalley AF, Bertschy G, Zullino D, Kosel M, Preisig M, Baumann P.

J Clin Psychopharmacol. 2001 Apr;21(2):229-34.

PMID:
11270921
20.

The effects of St John's wort (Hypericum perforatum) on human cytochrome P450 activity.

Wang Z, Gorski JC, Hamman MA, Huang SM, Lesko LJ, Hall SD.

Clin Pharmacol Ther. 2001 Oct;70(4):317-26.

PMID:
11673747

Supplemental Content

Support Center